The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets:
Chardan analyst Gbola Amusa maintained a Buy rating on the stock, but increased his price target from $37.50 to $60.
Amusa was inspired by both the mid-June removal of a clinical hold on SGT-001 and encouraging trial data from Solid, Sarepta Therapeutics Inc (NASDAQ: SRPT) and Pfizer Inc. (NYSE: PFE) proving the efficacy of AAV-based gene therapies in Duchenne muscular dystrophy.
“Positive early data from clinical trials from 3 different companies, to us, supports the utility of microdystrophin GT in a devastating disease with no effective approved therapies,” Amusa wrote in a note.
The analyst reiterated preference for Solid over Sarepta or Pfizer for its “superior” microdystrophin construct, vector and trial design.
Based on the study developments, Chardan anticipates launch of AAV-based therapies in 2022 rather than the previously estimated 2023, with 66.5 percent adoption among U.S. DMD patients by 2030.
With Solid expected to seize 25 percent to 37.5 percent of that market, Amusa forecasts 2024 sales of SGT-001 at $2.76 billion.
Shares last closed at $42.07.
Goldman Sachs Gets Firm On Solid Biosciences
Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'
Latest Ratings for SLDB
|Mar 2018||JP Morgan||Downgrades||Neutral||Underweight|
|Feb 2018||Chardan Capital||Initiates Coverage On||Buy|
View More Analyst Ratings for SLDB
View the Latest Analyst Ratings
See more from Benzinga
- The IPO Outlook For The Week: Shipping, Medtech, Mobility And Retail
- Trump Threatens 20% Tariffs On EU Cars
- Bernstein: Tesla's Auto, Services Gross Margins Don't Add Up
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.